Navigation Links
Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Date:6/18/2013

NESS ZIONA, Israel, June 18, 2013 /PRNewswire/ --

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment of moderate-to-severe acute pain.

US Patent number 8,410,176 B2 is titled Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds. Mapi's innovative process enables the company to obtain Tapentadol in an optically active pure form.  The process is cost effective, uses easily available reagents and fits scalable industrial processes.

Tapentadol is indicated for the relief of moderate-to-severe acute pain. This segment of pain relievers has continuously grown during the last decade as a result of improved delivery technologies, increased physician recognition of the need for effective pain treatment, and the rising requirement for pain medication by the growing ageing population.  

"The patent acceptance announced today is Mapi's second in just one month. The first was for a long acting depot formulation of Glatiramer Acetate for the treatment of MS. Both patents strengthen Mapi's patent position, support the business plan and advance the company one step closer to bringing patients improved medications at affordable prices," said Mapi Pharma President & CEO Mr. Ehud Marom. "The pain relief market requires a specific expertise in dealing with potent pharmaceuticals. Mapi is uniquely positioned to answer the growing needs of this market."

The moderate-to-severe acute pain relief market i
'/>"/>

SOURCE Mapi Pharma Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... reason people over 60 are not donor candidates for ... with time, making the elderly prone to life-threatening infection ... team now has discovered a reason why. , "We ... of blood-forming cells to maintain blood production over time ... that could be restored for rejuvenation therapies," said Emmanuelle ...
(Date:7/31/2014)... 31, 2014 The SNIS Foundation recognized ... to fund a translational research project.  The first ... gift was presented at the Society of NeuroInterventional ... Colorado Springs, CO. ... to neurovascular conditions, SNIS formed the SNIS Foundation, ...
(Date:7/31/2014)... 2014 According to a new ... Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ... Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry ... 2019," the global electrodes market for medical devices was ... estimated to reach a market worth USD 1,451.2 million ...
(Date:7/31/2014)... China , July 31, 2014 ... Irys™System by BGI , the world,s ... comprehensive exploration of human structural variation (SV) and to ... including those where no reference exists. In addition, BioNano ... for multiplexing on the Irys System, enabling significantly higher ...
Breaking Biology Technology:Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... H. Paul Dorman, Chairman,and Chief Executive Officer of ... has signed a definitive agreement to sell its,dermatology ... VRX )., Under the terms of ... shares of Coria from DFB Pharmaceuticals, Inc., and ...
... today announced that for the second year, it will ... hospitals, health systems and,community health clinics improve patient safety ... Patient Safety Grant Program in August,2007 as the first ... sector, and,received applications from more than 10 percent of ...
... 17 Quark Pharmaceuticals, Inc.,a development-stage ... interference (RNAi)-based therapeutics, today announced the,presentation ... RNAi Europe, taking place,September 16-18, 2008 ... scientists,Igor Mett, Hagar Kalinski, and Hagit ...
Cached Biology Technology:DFB Sells Coria Labs to Valeant Pharmaceuticals 2DFB Sells Coria Labs to Valeant Pharmaceuticals 3Cardinal Health Invites Health Care Providers to Apply for $1 Million in Grants to Fund Patient Safety Initiatives 2Cardinal Health Invites Health Care Providers to Apply for $1 Million in Grants to Fund Patient Safety Initiatives 3Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 3
(Date:7/31/2014)... The enormous conflagration known as the Rim Fire was ... among mature trees, when it entered the backcountry of ... August 2013. But inside the park, the battle began ... management decisions and drought can combine to fuel large, ... park, it eventually encountered lands where fire had been ...
(Date:7/31/2014)... Florida State University researcher found that bacteria in the ... of the oil released during the Deepwater Horizon spill ... most toxic contaminants. , In two new studies conducted ... found a species of bacteria called Colwellia ... and xylene compounds that were released as part of ...
(Date:7/31/2014)... July 31, 2014 NXT-ID, Inc., (NXTD: OTCQB) a ... market, reminds investors and consumers wanting to learn ... it will be on-air today, July 31 st ... wallet will be featured in a segment of ... that airs on the History Channel, FYI Network ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3
... led by Johns Hopkins scientists has,found the first ... immune,system's remarkable ability to recognize and respond to ... family of genes whose,only apparent function is to ... cut themselves out of the genetic material, and ...
... Health Department today issued a public health advisory after reporting ... highly drug resistant strain of HIV in a New York ... have occurred in mid-October 2004, to a largely untreatable strain ... health officials, the man -- who had previously had five ...
... President and Director of Research at the ... ,the release of a new approach to simulation ... of Nature,Biotechnology.,The research article, entitled "Automatic generation ... ,describes MSI's discrete stochastic event simulator, which keeps ...
Cached Biology News:UCSD Discovery Shows How Embryonic Stem Cells Perform 'Quality Control' Inspections 2UCSD Discovery Shows How Embryonic Stem Cells Perform 'Quality Control' Inspections 3NYC's First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 2MSI releases 'moleculizer' - a new approach to simulation of intracellular biochemical networks 3
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Rabbit anti-Junctophilin-4 (C-term)...
... CopyControl™ PCR Cloning Kits are designed to speed ... that all PCR products, regardless of sequence or ... PCR products including those that are difficult to ... may be unstable or code for potentially detrimental ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Biology Products: